Evidence map›Paper›PMID 37425961›Full record

ArticlebioRxiv : the preprint server for biology2023

A bistable inhibitory OptoGPCR for multiplexed optogenetic control of neural circuits.

Jonas Wietek, Adrianna Nozownik, Mauro Pulin, Inbar Saraf-Sinik, Noa Matosevich, Daniela Malan, Bobbie J Brown, Julien Dine, Rivka Levy, Anna Litvin and 12 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 6 countries.

Jonas WietekDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Adrianna NozownikCenter for Molecular Neurobiology, Hamburg, Germany.
Mauro PulinCenter for Molecular Neurobiology, Hamburg, Germany.
Inbar Saraf-SinikDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Noa MatosevichSagol school of neuroscience, Tel Aviv University, Tel Aviv, Israel.
Daniela MalanInstitut für Physiologie I, Universität Bonn, Bonn, Germany.
Bobbie J BrownWashington University Pain Center, Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, USA.
Julien DineDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Rivka LevyDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Anna LitvinDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Noa RegevDepartment of Physiology and Pharmacology, Tel Aviv University, Tel Aviv, Israel.
Suraj SubramaniamDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Eyal BittonDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Asaf BenjaminDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Bryan A CopitsWashington University Pain Center, Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, USA.
Philipp SasseInstitut für Physiologie I, Universität Bonn, Bonn, Germany.
Benjamin R RostGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Dietmar SchmitzGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Peter SobaInstitute of Physiology and Pathophysiology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Yuval NirSagol school of neuroscience, Tel Aviv University, Tel Aviv, Israel.
J Simon WiegertCenter for Molecular Neurobiology, Hamburg, Germany.
Ofer YizharDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Weizmann Institute of Science · ILTel Aviv University · ILUniversity of Bonn · DEUniversität Hamburg · DEWashington University in St. Louis · USBoehringer Ingelheim (Germany) · DECentre National de la Recherche Scientifique · FRGerman Center for Neurodegenerative Diseases · DEMax Delbrück Center · DE

Funding

Next Generation Opto-GPCRs for Neuromodulatory ControlU01NS128537 · NINDS · UNIVERSITY OF WASHINGTON · PI Andre Berndt, Michael R. Bruchas · 2023 to 2026
$4.4M
NINDS NIH HHS U01 NS128537
6 · The paper itself

Abstract

Information is transmitted between brain regions through the release of neurotransmitters from long-range projecting axons. Understanding how the activity of such long-range connections contributes to behavior requires efficient methods for reversibly manipulating their function. Chemogenetic and optogenetic tools, acting through endogenous G-protein coupled receptor (GPCRs) pathways, can be used to modulate synaptic transmission, but existing tools are limited in sensitivity, spatiotemporal precision, or spectral multiplexing capabilities. Here we systematically evaluated multiple bistable opsins for optogenetic applications and found that the

Identifiers

PMID37425961
PMCPMC10327178
OpenAlexW4382874541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.